Market Overview

More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data

Share:
More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better than what analysts were expecting.

Barclays' Geoff Meacham upgraded Vertex's stock from Equal-Weight to Overweight with a price target boosted from $115 to $180 as the company's phase 2 data was not only a "an unequivocal success" but represents a "major de-risking event."

"We find the rapid ~10% FEV-1 benefit in het/min CF patients across three different combos quite remarkable and with a dramatic sweat chloride benefit (and good tolerability) as a bonus," Meacham wrote.

By the analyst's own admission, he has been late to the "bull camp" on Vertex's stock due to prior "unimpressive" prior data reads, which supported an Equal Weight rating. But this is now clearly in the past and it's not too late to buy shares. The company's CF franchise can now be viewed as "highly defensible" and represents a major new opportunity.

Looking forward, the analyst is now projecting a conservative $2.7 billion revenue estimate in triple combo sales along with increased penetration/compliance in F508del homozygous CF patients for a potential triple combo.

Bottom line, the company's phase 2 read-out adds "meaningfully more confidence in the viability of the triple combo" which also signals an accelerated development path.

Related Links:

The Market In 5 Minutes

25 Stocks Moving In Wednesday's Pre-Market Session

Latest Ratings for VRTX

DateFirmActionFromTo
Nov 2019ReiteratesBuy
Nov 2019MaintainsOverweight
Nov 2019Initiates Coverage OnBuy

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings

Posted-In: Cystic Fibrosis Geoff Meacham Lung Drugs vertexAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga

 

Related Articles (VRTX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SRCMorgan StanleyMaintains56.0
RNGBank of AmericaReiterates198.0
BF/BMorgan StanleyMaintains60.0
ADBEMorgan StanleyMaintains410.0
LULUBank of AmericaReiterates268.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Axiom's Gordon Johnson, Noted Solar Bear, Upgrades First Solar To Buy

Benzinga's Top Upgrades, Downgrades For July 19, 2017